Moleculin Biotech Stock Forum

$Moleculin Biotech(MBRX.US)$
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
Moleculin Biotech has completed its End of Phase 2 (EOP2) meeting with the FDA for its Phase 1B/2 clinical trial of Annamycin combined with Cytarabine for treating AML (MB-106). The meeting focused on reviewing clinical data and planning the next steps, with official outcomes expected by Q3 2024. Interim results show that out of 22 enrolled subjects, 45% achieved a composite complete remiss...

$Moleculin Biotech(MBRX.US)$ Moleculin Announces Additional Positive Preliminary Interim Data From Aml Clinical Trial! 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study! Annamycin Continues to Demonstrate No Cardiotoxicity! Current Median Durability of Response (Mdor) of Crc's = 6 Months and Increasing (N=9) in Study

$Moleculin Biotech(MBRX.US)$ Means the stock will go on a run soon which will then be stopped by adding shares. If you buy you might wanf try to sell before it reaches 30% gains.

$Moleculin Biotech(MBRX.US)$ Moleculin Announces Commencement of Nih-Funded Phase 2 Clinical Trial of Stat3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

$Moleculin Biotech(MBRX.US)$ Reuters· 1 min ago
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

$Moleculin Biotech(MBRX.US)$
NEWS
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
The issuance of the U.S. Patent for Lipid-Based Delivery Technology for Annamycin provides composition protection until 2040, with the potential for extension, enhancing the Company's intellectual property portfolio.
Annamycin, the next-generation anthracycline developed by Moleculin, has demonstrated promising results in clinical studies, showing non-cardiotoxic...

$Moleculin Biotech(MBRX.US)$ Reuters· 1 min ago
Moleculin Reports Higher Aml Complete Remission (Cr) Rates and Significant Durability With Additional Interim Subject Data

$Moleculin Biotech(MBRX.US)$ European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (Aml)

$Moleculin Biotech(MBRX.US)$
NEWS
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

$Moleculin Biotech(MBRX.US)$ wtf is going on? no news?